Phase 3 Cholesterol Clinical Trials
14 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–14 of 14 trials
Recruiting
Phase 3
Long-term Safety and Tolerability of Inclisiran in Participants With HeFH or HoFH Who Have Completed the Pediatric ORION-16, ORION-13, ORION-20, or ORION-19 Studies
Heterozygous or Homozygous Familial Hypercholesterolemia
Novartis Pharmaceuticals195 enrolled52 locationsNCT05682378
Recruiting
Phase 2Phase 3
A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029)
Heterozygous Familial Hypercholesterolemia (HeFH)
Merck Sharp & Dohme LLC153 enrolled24 locationsNCT07058077
Recruiting
Phase 3
A Study to Evaluate the Safety, Efficacy of SYH2053 as Monotherapy in Chinese Participants With Non-familial Hypercholesterolemia or Mixed Hyperlipidemia
Non-familial Hypercholesterolemia and Mixed Hyperlipidemia
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.760 enrolled2 locationsNCT07421297
Recruiting
Phase 3
A Phase 3 Study of Zodasiran in Adolescent and Adult Subjects With Homozygous Familial Hypercholesterolemia (YOSEMITE)
Homozygous Familial Hypercholesterolemia
Arrowhead Pharmaceuticals60 enrolled22 locationsNCT07037771
Recruiting
Phase 3
Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With Homozygous Familial Hypercholesterolemia
Familial Hypercholesterolemia - Homozygous
Novartis Pharmaceuticals9 enrolled18 locationsNCT06597006
Recruiting
Phase 3
Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial Hypercholesterolemia
Familial Hypercholesterolemia - Heterozygous
Novartis Pharmaceuticals51 enrolled66 locationsNCT06597019
Recruiting
Phase 3
A Study on Efficacy and Safety of HST101 in Chinese Patients with Hypercholesterolemia
DyslipidemiasHypercholesterolemia
Hasten Biopharmaceutical Co., Ltd.210 enrolled18 locationsNCT06568471
Recruiting
Phase 3
efficacy of LOw dose antihypertensive and lipid lowering pill combinations To improve stroke oUtcomeS (LOTUS)
HypercholesterolaemiaHypertensionTransient Ischaemic Attack+1 more
The George Institute for Global Health Australia400 enrolled14 locationsACTRN12624001279516
Recruiting
Phase 3
Efficacy and Safety of JS002 as Monotherapy in Patients With Primary Hypercholesterolaemia and Mixed Dyslipidemia
Primary Hypercholesterolaemia and Mixed Dyslipidemia
Shanghai Junshi Bioscience Co., Ltd.582 enrolled1 locationNCT05621070
Recruiting
Phase 2Phase 3
Effects of Phytoestrogen From Pueraria Mirifica in Improvement of Serum Lipid Parameters in Postmenopausal Women
DyslipidemiasPostmenopausal SymptomsHypercholesterolemia+3 more
Dhurakij Pundit University10 enrolled1 locationNCT06220266
Terminated
Phase 3
Evaluating the efficacy and adherence of administration of a PCSK9 inhibitor Alirocumab in Aboriginal participants with hypercholesterolaemia
Hypercholesterolaemia
South Australian Health and Medical Research Institute200 enrolled3 locationsACTRN12616000871448
Completed
Phase 2Phase 3
Dose response study of phytosterols in tablet dosage in adults with primary hypercholeterolemia
Primary hypercholesterolemia
Mayne Health Consumer Products80 enrolled1 locationACTRN12605000303640
Completed
Phase 3
Study on the Safety and Efficacy of Sylvan Red Yeast Rice in Adults with Primary Hypercholesterolemia
Hypercholesterolemia
Sylvan Australia Pty Ltd72 enrolled1 locationACTRN12605000288628
Completed
Phase 3
Dose Response Study of a Complementary Medicine Formulation in Primary Hypercholesterolaemia
Primary Hypercholesterolaemia
Pathways40 enrolled1 locationACTRN12605000232639